- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06164951
A Study to Evaluate the Efficacy and Safety of Infigratinib in Children and Adolescents With Achondroplasia (PROPEL3)
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Infigratinib in Children 3 to <18 Years of Age With Achondroplasia: PROPEL 3
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Capital Federal
-
Buenos Aires, Capital Federal, Argentina, C1245AAM
- QED Investigative Site
-
-
-
-
Victoria
-
Parkville, Victoria, Australia, 3052
- QED Investigative Site
-
-
-
-
Alberta
-
Edmonton, Alberta, Canada, T6G 1C9
- QED Investigative Site
-
-
Ontario
-
Ottawa, Ontario, Canada, K1H 8L1
- QED Investigative Site
-
-
Quebec
-
Montréal, Quebec, Canada, H3C 3J7
- QED Investigative Site
-
-
-
-
-
Bron, France, 69677
- QED Investigative Site
-
Paris, France, 75015
- QED Investigative Site
-
Toulouse, France, 31059
- QED Investigative Site
-
-
-
-
Sachsen-Anhalt
-
Magdeburg, Sachsen-Anhalt, Germany, 39120
- QED Investigative Site
-
-
-
-
-
Milano, Italy, 20122
- QED Investigative Site
-
Rome, Italy, 00168
- QED Investigative Site
-
-
-
-
-
Bergen, Norway, 5021
- QED Investigative Site
-
Oslo, Norway, 0372
- QED Investigative Site
-
-
-
-
-
Singapore, Singapore, 229899
- QED Investigative Site
-
-
-
-
-
Madrid, Spain, 28046
- QED Investigative Site
-
Málaga, Spain, 29010
- QED Investigative Site
-
Vitoria-Gasteiz, Spain, 01008
- QED Investigative Site
-
-
-
-
-
Birmingham, United Kingdom, B4 6NH
- QED Investigative Site
-
Bristol, United Kingdom, BS2 8AE
- QED Investigative Site
-
Glasgow, United Kingdom, G12 0XH
- QED Investigative Site
-
London, United Kingdom, SE1 7EH
- QED Investigative Site
-
Manchester, United Kingdom, M13 9WL
- QED Investigative Site
-
Sheffield, United Kingdom, S10 2TH
- QED Investigative Site
-
-
-
-
California
-
San Francisco, California, United States, 94110
- QED Investigative Site
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- QED Investigative Site
-
-
Maryland
-
Baltimore, Maryland, United States, 21287
- QED Investigative Site
-
-
Missouri
-
Columbia, Missouri, United States, 65203
- QED Investigative Site
-
-
Ohio
-
Cincinnati, Ohio, United States, 45229
- QED Investigative Site
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- QED Investigative Site
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53705
- QED Investigative Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Inclusion Criteria:
Subject must be 3 to <18 years of age at screening with growth potential defined as annualized height velocity of >1.5 cm/year over a period of at least 6 months, pubertal Tanner stage ≤4, and bone age ≤13 years in females and ≤15 years in males.
Type of Subject and Disease Characteristics
- Subjects who have a diagnosis of ACH that has been documented clinically and confirmed by genetic testing.
- Subjects must have completed at least 26 weeks in the PROPEL (QBGJ398-001) study before study entry.
- Subjects are able to swallow oral medication.
- Subjects and parent(s), legal guardian(s), or caregivers are willing and able to comply with study visits and study procedures.
- Subjects are ambulatory and able to stand without assistance. Sex and Contraceptive/Barrier Requirements
- Negative pregnancy test in girls ≥10 years of age or girls of any age who have experienced menarche.
If sexually active, subjects must be willing to use a highly effective method of contraception while taking study drug and for 3 months after the last dose of study drug.
Informed Consent
- Signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form and in this protocol, must be obtained for each subject from their parent(s) or legal guardian and signed informed consent/assent must be obtained from the subject (when applicable)
Exclusion Criteria:
Exclusion Criteria Medical Conditions
- Subjects who have hypochondroplasia or short stature condition other than ACH.
- Significant concurrent disease or condition that, in the view of the investigator and/or sponsor, would confound assessment of efficacy or safety of infigratinib.
- Current evidence of clinically significant corneal or retinal disorder/keratopathy confirmed by ophthalmic examination.
- Concurrent circumstance, disease or condition that, in the view of the investigator and/or sponsor, would interfere with study participation or safety evaluations and/or would require treatment with a prohibited medication, and/or would place the subject at high risk for poor treatment compliance or for not completing the study.
- History and/or current evidence of extensive ectopic tissue calcification.
History of malignancy.
Prior/Concomitant Therapy
- Having received or planning to receive treatment with any other investigational or approved product for the treatment of ACH or short stature.
- Regular long-term treatment (≥3 weeks) with supraphysiologic doses of glucocorticoid therapy (ie, >15 mg/m2/day of hydrocortisone or equivalence) or treatment with glucocorticoids at anti-inflammatory doses for over 3 weeks within 6 months of the screening visit (low-dose ongoing inhaled steroid for asthma is acceptable).
- Previous limb-lengthening surgery at any time or planned/expected to have limb-lengthening surgery or guided growth surgery during the study period. Guided growth surgery with plates removed at least 12 months prior to screening is allowed.
- Currently receiving treatment with agents that are known strong inducers or inhibitors of CYP3A4 or prolonged treatment (>1 week) with medications that alter the pH of the gastrointestinal tract or antiepileptic drugs that are CYP3A4 and/or P-gp inducers, including carbamazepine, phenytoin, phenobarbital, and primidone.
Current evidence of endocrine alterations of calcium/phosphorus homeostasis.
Diagnostic assessments
Subjects who have significant abnormality in screening laboratory results.
Other Exclusions
- Having had a fracture of the long bones (ie, extremities) or spine within 12 months prior to screening.
- Pregnant or breastfeeding at the screening visit or planning to become pregnant (self or partner) at any time during the study.
- Allergy or hypersensitivity to any components of the study drug.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Infigratinib 0.25 mg/kg/day
Infigratinib at 2, 3.5, 5, 7, 10 mg
|
Daily doses of oral Infigratinib (sprinkle capsules) at 2, 3.5, 5, 7, 10 mg
|
Placebo Comparator: Placebo 0.25 mg/kg/day
Placebo Comparator at 2, 3.5, 5, 7, 10 mg
|
Daily doses of oral Placebo Comparator (sprinkle capsules) at 2, 3.5, 5, 7, 10 mg
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline (BL) in annualized height velocity (cm/year)
Time Frame: Week 52
|
Week 52
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change from BL in height Z-score (in relation to ACH tables)
Time Frame: Week 52
|
Week 52
|
|
Change from BL in upper to lower body segment ratio
Time Frame: Week 52
|
Week 52
|
|
Change from BL in height Z-score (in relation to non-ACH tables)
Time Frame: Week 52
|
Week 52
|
|
Annualized height velocity (cm/year)
Time Frame: Week 52
|
Week 52
|
|
Absolute and change from baseline in upper arm to forearm length ratio (cm)
Time Frame: Week 52
|
Week 52
|
|
Absolute and change from baseline in upper leg to lower leg length ratio (cm)
Time Frame: Week 52
|
Week 52
|
|
Absolute and change from baseline in arm span (cm) to standing height ratio
Time Frame: Week 52
|
Week 52
|
|
Absolute and change from baseline in head circumference (cm) to standing height ratio
Time Frame: Week 52
|
Week 52
|
|
Absolute value and change in body mass index
Time Frame: Week 52
|
Week 52
|
|
Incidence of adverse events
Time Frame: Week 52
|
Week 52
|
|
Change from BL in annualized height velocity (cm/year) in children 5 years old and older, compared to placebo
Time Frame: Week 52
|
Week 52
|
|
Change from BL in the Physical Functioning dimension of the Pediatric Quality of Life Generic Core Scale Short Form
Time Frame: Week 52
|
Scale scores 0-100.
Higher score=better Health-Related Quality of Life
|
Week 52
|
Change in psychomotor function assessed by age-appropriate computerized tests (Detection Test), compared to placebo
Time Frame: Week 52
|
Lower score=better performance.
Range values=2-6
|
Week 52
|
Change from BL in attention assessed by age-appropriate computerized tests (Identification Test)
Time Frame: Week 52
|
Lower score=better performance.
Range values=2-6
|
Week 52
|
Change from BL in visual learning assessed by age-appropriate computerized tests (One Card Learning Test)
Time Frame: Week 52
|
Higher score=better performance.
Range values=0-1.6
|
Week 52
|
Change from BL in working memory assessed by age-appropriate computerized tests (One Back Test)
Time Frame: Week 52
|
Lower score=better performance.
Range values=2-6
|
Week 52
|
Pharmacokinetic profile of infigratinib by assessment of maximum concentration (Cmax)
Time Frame: Week 52
|
Week 52
|
|
Pharmacokinetic profile of infigratinib by assessment of time-to-maximum concentration (Tmax)
Time Frame: Week 52
|
Week 52
|
|
Evaluate the acceptability and palatability of infigratinib using a 5-point hedonic scale
Time Frame: Week 13
|
Week 13
|
|
Change from BL in collagen X marker concentration (ug/L)
Time Frame: Week 52
|
Week 52
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: QED Therapeutics, Inc. Medical Director, Clinical Development, QED Therapeutics
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
- Growth
- FGFR3
- Genetic diseases
- Bone disease
- Dwarfism
- Skeletal dysplasia
- Endochondral ossification
- Fibroblast growth factor receptor 3
- Endochondral bone formation
- Short-limb disproportionate dwarfism
- Musculoskeletal diseases
- Osteochondrodysplasia
- Long-term treatment
- Quality of life in achondroplasia
- Functionality in achondroplasia
- Annualized height velocity
Additional Relevant MeSH Terms
Other Study ID Numbers
- QBGJ398-303
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Achondroplasia
-
GeneScience Pharmaceuticals Co., Ltd.Tongji Hospital; Shengjing Hospital; Shandong Provincial Hospital; Children's Hospital... and other collaboratorsRecruiting
-
Johns Hopkins UniversityUniversity of Wisconsin, Madison; University of Texas; BioMarin Pharmaceutical; Alfred I. duPont Hospital for Children and other collaboratorsEnrolling by invitationAchondroplasia
-
PfizerTerminatedAchondroplasiaBelgium, United States, Japan, Australia, Portugal, Denmark, Italy, Spain
-
PfizerTerminatedAchondroplasiaUnited States, Australia, Belgium, Denmark, Italy, Portugal, Spain
-
BioMarin PharmaceuticalActive, not recruitingAchondroplasiaUnited States, Australia, Japan, United Kingdom
-
BioMarin PharmaceuticalActive, not recruitingAchondroplasiaAustralia, United Kingdom
-
BioMarin PharmaceuticalCompletedAchondroplasiaUnited States, Australia, United Kingdom, Japan, Spain, Turkey
-
BioMarin PharmaceuticalPicnicHealthRecruitingAchondroplasiaUnited States
-
Ascendis Pharma Growth Disorders A/SActive, not recruitingAchondroplasiaUnited States, Denmark, Ireland, New Zealand, Australia, Canada, Spain
-
Ascendis Pharma A/SActive, not recruitingAchondroplasiaUnited States, Australia, Austria, Denmark, Germany, Ireland, New Zealand, Portugal
Clinical Trials on Infigratinib 0.25 mg/kg/day
-
QED Therapeutics, Inc.RecruitingAchondroplasiaUnited States, Spain, United Kingdom, France, Canada, Australia
-
ReveraGen BioPharma, Inc.National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaboratorsCompletedDuchenne Muscular DystrophyUnited States, Canada, United Kingdom, Sweden, Australia, Israel
-
ReveraGen BioPharma, Inc.National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) and other collaboratorsCompletedDuchenne Muscular DystrophyUnited States, Canada, United Kingdom, Sweden, Australia, Israel
-
ReveraGen BioPharma, Inc.University of Pittsburgh; Cooperative International Neuromuscular Research...CompletedDuchenne Muscular DystrophyUnited States, Canada, United Kingdom, Sweden, Australia, Israel
-
PfizerTerminatedMultiple SclerosisUnited States
-
University of OxfordMahidol Oxford Tropical Medicine Research Unit; Nangarhar UniversityCompletedVivax MalariaAfghanistan
-
Warner ChilcottCompleted
-
Hansa Biopharma ABUniversity College London HospitalsTerminatedPurpura, Thrombotic ThrombocytopenicUnited Kingdom
-
NeuroVive Pharmaceutical ABCompleted
-
University of California, San FranciscoBill and Melinda Gates Foundation; Wellcome Trust; Malaria Research and Training... and other collaboratorsCompleted